A clinic outside the UK that runs ads aimed at people in the UK is held to the UK's advertising rules, and in March 2026 the UK regulator showed it is watching clinics abroad closely. The regulator is the Advertising Standards Authority, or ASA. The rules it applies are the CAP Code, written by the Committee of Advertising Practice. On 12 March 2026 the ASA published an enforcement report on cosmetic surgery abroad. For an Indian clinic in medical travel or aesthetic care that wants UK patients, it reads like a checklist of what not to do. This note sets out what the report says and the controls I would run. It is not legal advice.

Key points

  • The ASA's report covers paid ads on Meta's social media platforms from clinics based abroad.
  • Two other ASA and CAP pages are worth reading with the report.
  • I would give every ad aimed at UK audiences an owner, a written check before it runs and a record of who approved it.

What the ASA found

The ASA's report covers paid ads on Meta's social media platforms from clinics based abroad. It ran from December 2024 to December 2025. The ASA said it captured more than 4,000 paid ads for cosmetic surgery across two phases of monitoring.

Two problems stood out in the report. The first was "mommy makeover" packages that, in the ASA's words, exploited body insecurities in new mothers. The second was time-limited offers that pressured people into making rushed decisions about surgery.

The ASA then acted. It contacted advertisers whose ads breached the CAP Code and told them to remove or amend the problem claims. Where advertisers did not respond, it escalated the issue through Meta. The ASA's report says compliance rose from 61.4% to 86.9% in the first phase and from 41.7% to 70.6% in the second. The ASA says it tracks these ads with an AI-based monitoring system, so this is not a one-off sweep.

Why this matters for a clinic in India

This matters because an ad is the first promise a patient hears, and an ad that rushes or shames a patient starts the care relationship on pressure instead of evidence. A countdown timer on surgery tells the patient that speed matters more than the decision. That is the opposite of what a careful clinic wants a patient to believe.

It matters for the business too. An ad that is removed after a regulator's letter wastes the spend. Worse, a UK patient who later reads about the report may wonder what else the clinic cut corners on.

For India, the stakes are larger than one clinic. An Indian clinic that meets the UK standard in its ads shows overseas patients the same discipline they should expect from its care, and that is how India competes on evidence rather than on pressure.

An ad that needs a countdown is selling the clock, not the care.

Rules a clinic often misses

Two other ASA and CAP pages are worth reading with the report.

The first is about prescription-only medicines. CAP's guidance on botulinum toxin, the anti-wrinkle injection, says it is a prescription-only medicine and cannot be advertised to the public, under CAP rule 12.12 and regulations from the MHRA, the UK medicines regulator. The same page says it can be mentioned on a clinic's own website only as a possible outcome of a consultation or in a price list, and only in a purely informational way. It says it cannot be mentioned in paid advertising or on social media.

The second is about age. The ASA's regulatory statement on cosmetic interventions says that rules preventing these ads from being directed at under-18s took effect from 25 May 2022. The same CAP guidance adds that ads for non-surgical cosmetic treatments cannot appear in non-broadcast media where under-18s make up 25% or more of the audience.

How I would run ad compliance for UK audiences

I would give every ad aimed at UK audiences an owner, a written check before it runs and a record of who approved it. The owner sits in marketing. The check is a short list drawn from the rules above. The record shows the ad, the date, the audience setting and the approver.

The pre-run check needs only a few questions:

1. Does the ad set a deadline, a countdown or a "today only" price for a surgical procedure? If so, remove it. 2. Does it play on how a person feels about their body after pregnancy, ageing or weight change? If so, rewrite it. 3. Does it mention a prescription-only medicine, directly or by a nickname? If so, remove it. 4. Is the audience set to exclude under-18s? 5. Can every claim in the ad be shown to be true with a document the clinic holds?

I would also run a monthly sample. A second person pulls ten live ads at random and runs the same check. Any failure goes back to the owner with a date to fix it.

Where the trade-off sits

These controls cost reach. A time-limited offer may well lift clicks in the short term. I would accept fewer clicks. A patient who books because a timer was running has not yet decided, and a patient who has not decided is the one most likely to cancel or complain.

There is also a cost in speed. A written check and an approver add a day to each campaign. I would keep that day. It is cheaper than a regulator's letter, and it gives the clinic a record to show if a question ever comes. Clinics in India that adopt this before they are asked will have an easier time with every overseas regulator, not only the UK's.

Sources

Questions people ask

Do UK advertising rules apply to a clinic based in India?

The ASA's March 2026 report examined clinics based abroad that ran paid ads on Meta, and it contacted advertisers whose ads breached the CAP Code. So a clinic outside the UK that targets UK audiences should expect the same rules to be applied. This is not legal advice; a clinic should take advice on its own case.

What did the ASA find in ads for cosmetic surgery abroad?

The ASA said it captured more than 4,000 paid ads in two phases of monitoring between December 2024 and December 2025. It found packages that exploited body insecurities in new mothers and time-limited offers that pressured people into rushed decisions about surgery. Compliance improved after the regulator contacted advertisers.

Can a clinic advertise anti-wrinkle injections to UK patients?

Not when they use a prescription-only medicine such as botulinum toxin. CAP's guidance says it is a prescription-only medicine and cannot be advertised to the public, under CAP rule 12.12 and regulations from the MHRA. It may be mentioned on a clinic's own website only in limited, purely informational ways, such as a price list, and never in paid advertising or on social media.